FSTL3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-Myc in colorectal cancer

Haiyang Li,Na Zheng,Anning Guo,Weiwei Tang,Muxin Li,Yuanyuan Cao,Xinhua Ma,Hongyong Cao,Yong Ma,Hanjin Wang,Shuli Zhao

DOI: https://doi.org/10.1038/s41419-024-06469-0

2024-02-02

Cell Death and Disease

Abstract:Programmed cell death 1 ligand 1 (PDL1)/programmed cell death 1 (PD1) blockade immunotherapy provides a prospective strategy for the treatment of colorectal cancer (CRC), but various constraints on the effectiveness of the treatment are still remaining. As reported in previous studies, follistatin-like 3 (FSTL3) could mediate inflammatory response in macrophages by induction lipid accumulation. Herein, we revealed that FSTL3 were overexpressed in malignant cells in the CRC microenvironment, notably, the expression level of FSTL3 was related to tumor immune evasion and the clinical efficacy of anti-PD1 therapy. Further studies determined that hypoxic tumor microenvironment induced the FSTL3 expression via HIF1α in CRC cells, FSTL3 could bind to the transcription factor c-Myc (354–406 amino acids) to suppress the latter's ubiquitination and increase its stability, thereby to up-regulated the expression of PDL1 and indoleamine 2,3-dioxygenase 1 (IDO1). The results in the immunocompetent tumor models verified that FSLT3 knockout in tumor cells increased the proportion of CD8 + T cells in the tumor microenvironment, reduced the proportion of regulatory T cells (CD25 + Foxp3 + ) and exhausted T cells (PD1 + CD8 + ), and synergistically improved the anti-PD1 therapy efficacy. To sum up, FSTL3 enhanced c-Myc-mediated transcriptional regulation to promote immune evasion and attenuates response to anti-PD1 therapy in CRC, suggesting the potential of FSTL3 as a biomarker of immunotherapeutic efficacy as well as a novel immunotherapeutic target in CRC.

cell biology

What problem does this paper attempt to address?

This paper aims to explore the role of FSTL3 in colorectal cancer (CRC) and its relationship with tumor immune escape and anti - PD1 treatment responsiveness. Specifically, the study attempts to address the following issues:

1. **Expression level of FSTL3 in CRC**: Through single - cell transcriptome sequencing, immunofluorescence analysis, and experimental methods such as Western Blot and IHC, the study found that FSTL3 is highly expressed in cancer cells in CRC tissues, and its expression level is significantly higher than that in normal tissues.

2. **Relationship between FSTL3 and immune checkpoints**: Through data analysis of the TCGA CRC cohort, the study revealed that the expression of immune checkpoints (such as PDL1, IDO1, CD80, PD1, TIGIT, and CD276) was significantly up - regulated in the FSTL3 high - expression group.

3. **Relationship between FSTL3 and microsatellite instability (MSI)**: The study further found that the expression level of FSTL3 is closely related to microsatellite instability. The proportion of MSI - H tumors in the FSTL3 high - expression group is significantly increased, and the expression level of FSTL3 has a good effect on predicting microsatellite instability.

4. **Mechanism of up - regulated FSTL3 expression under hypoxic conditions**: The study explored the mechanism of up - regulated FSTL3 expression under hypoxic conditions and found that the hypoxia - inducible factor HIF - 1α plays a key role in this process. HIF - 1α promotes the expression of FSTL3 by binding to the potential binding sites in the FSTL3 promoter region.

5. **Positive regulatory effect of FSTL3 on PDL1 expression**: Through experiments of over - expressing and knocking down FSTL3, the study found that FSTL3 can up - regulate the expression of PDL1 by stabilizing the c - Myc protein and inhibiting its ubiquitination - mediated degradation, thus promoting tumor immune escape.

6. **Role of FSTL3 in anti - PD1 treatment**: The study also explored the role of FSTL3 in anti - PD1 treatment and found that high expression of FSTL3 will lead to increased resistance of CRC to PD1 antibody treatment. By knocking out FSTL3, the proportion of CD8+ T cells in the tumor microenvironment can be increased, and the proportions of regulatory T cells (CD25+Foxp3+) and exhausted T cells (PD1+CD8+) can be reduced, synergistically improving the effect of anti - PD1 treatment.

In conclusion, this study reveals the important role of FSTL3 in CRC immune escape and anti - PD1 treatment responsiveness, providing new biomarkers and potential treatment targets for CRC immunotherapy.